MEI Pharma's cancer drug misses main goals in mid-stage study

(Reuters) - MEI Pharma says its cancer drug failed to meet the main goal in a mid-stage study. The drug, pracinostat, in combination with chemotherapy drug azacitidine showed no difference in complete remission in previously untreated patients with myelodysplastic syndrome (MDS) - a type of blood cancer - against azacitidine alone. Complete remission implies the disappearance of all signs of cancer in response to treatment. It does not always constitute a cure. (Reporting by Rosmi Shaji in Bengaluru; Editing by Saumyadeb Chakrabarty) March 23, 2015 at 07:31AM

via Lazahealth.org